Labrys Biologics
San Francisco
About Labrys Biologics
Labrys Biologics Inc., a company focused on treatments for chronic migraine. Labrys Biologics has acquired worldwide rights to RN-307 from Pfizer Inc. RN-307 is an antibody for the treatment of chronic migraine.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $45.6M
- Funding stage: M&A
- Last round: Series A (Jan 2013)
- Website: labrysbiologics.com
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/labrys-biologics-1092710 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.